PharmaCyte Biotech, Inc. PMCB
As we kick off the start of a new trading week, our point of focus is going to be PMCB, a clinical stage biopharma company. The Biopharma/Biotech sector has been enjoying a resurgence of late, evidenced by many such plays that we’ve already run across this year. What sets PMCB apart from the rest is the versatility of its flagship product, which we believe has significant disruptive potential in the marketplace upon further development.
The nature of PMCB‘s patented Cell-in-a-Box® technology lends to its high development potential, as it is a cellular treatment delivery method which could theoretically be utilized for virtually limitless applications. It can be generically referred to as a ‘cellulose-based live cell encapsulation technology’, but to explain exactly what that means to the average person requires a bit more detail.
Cellulose is an organic polymer which is the most abundant such compound in nature, being found in varying quantities in the cell walls of all plants. It is chemically inert, and its insolubility in the human body makes it an ideal carrier for potential treatments. Microscopic capsules constructed of cellulose are filled with living cells, either lab-engineered or cultured from natural compounds, and introduced into the body. The capsules have micropores which do not allow for the escape of the contained cells, but are sufficient in size to facilitate introduction of essential nutrients and beneficial substances produced by the cells. >> LEARN MORE
PMCB has several irons in the fire with Cell-in-a-Box®. It has been granted orphan-drug status by the FDA relating to the treatment of advanced pancreatic cancer, and the company currently has three separate Phase II trials underway testing its efficacy from multiple angles. >> LEARN MORE
In addition, the company has preclinical trials involving its technology’s implementation using cannabinoids, an active compound found in marijuana, which has the potential to help PMCB expand into another trendy sector. There are a number of other treatments in the preclinical phase, including those that treat diabetes, as well as brain and breast cancer.
Goldman Smallcap Research recently released a report on PMCB wherein senior analyst Rob Goldman referred to the company as a “prototypical acquisition target”. Based on what we ourselves have learned about PharmaCyte and the future potential of its many treatments, we’d find it hard to deny the possibility of PMCB getting picked up by a large pharmaceutical company at some point. >> GOLDMAN REPORT
FDA’s Record Approvals Bode Well for PharmaCyte’s Cancer Treatments (Tue 8:45AM EDT)
_____________________
CHART:
We can also see potential in the chart in the near-term. PMCB recently ran off of its 52-week low of .10, making a solid move to .16. Yesterday the stock began to consolidate off of that spike, and there could be a considerable bounce once the stock finds support. We’ll be looking for that to happen at or above the current 50DMA of .12. Beyond that, if PMCB can break resistance at .16, the next patch is sitting at the 200DMA, just shy of .20. The stock was trading at that level back in January, and a return there from current prices would leave us open to gains in the neighborhood of 40% or more.
We’ve also prepared a video presentation of the chart for your convenience:
Learn More About PMCB @ PharmacyteBiotech.com